Take Care of the Fast-in-Human Study.
作者信息
van Hoogdalem E-J
机构信息
PRA Health Sciences, Raleigh, Groningen, The Netherlands.
出版信息
Clin Transl Sci. 2017 May;10(3):122-123. doi: 10.1111/cts.12437. Epub 2017 Jan 10.
Abstract
摘要
相似文献
1
Take Care of the Fast-in-Human Study.
Clin Transl Sci. 2017 May;10(3):122-123. doi: 10.1111/cts.12437. Epub 2017 Jan 10.
2
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
Clin Pharmacol Ther. 2022 Feb;111(2):391-403. doi: 10.1002/cpt.2290. Epub 2021 Jun 24.
3
Lessons from the fatal French study BIA-10-2474.
BMJ. 2016 May 18;353:i2727. doi: 10.1136/bmj.i2727.
4
FAAH inhibitors in the limelight, but regrettably.
Int J Clin Pharmacol Ther. 2016 Jul;54(7):498-501. doi: 10.5414/CP202687.
5
Commentary: Fatal French Clinical Trial: What Can We Learn from What Went Wrong?
CNS Neurol Disord Drug Targets. 2016;15(7):752-3. doi: 10.2174/187152731507160808200336.
6
Commentary on BIA 10-2474.
Regul Toxicol Pharmacol. 2020 Mar;111:104541. doi: 10.1016/j.yrtph.2019.104541. Epub 2019 Nov 20.
7
Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase.
ChemMedChem. 2018 Oct 22;13(20):2177-2188. doi: 10.1002/cmdc.201800393. Epub 2018 Sep 11.
8
Tirbanibulin (Klisyri) for the Treatment of Actinic Keratosis.
Am Fam Physician. 2021 Nov 1;104(5):519-520.
9
Lead Essay: Money, Equity and Access to Medicines.
J Bioeth Inq. 2020 Mar;17(1):25-27. doi: 10.1007/s11673-020-09966-x.
10
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.
N Engl J Med. 2016 Nov 3;375(18):1717-1725. doi: 10.1056/NEJMoa1604221.
引用本文的文献
1
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach.
Br J Clin Pharmacol. 2025 Sep;91(9):2705-2710. doi: 10.1002/bcp.70090. Epub 2025 May 15.
本文引用的文献
1
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.
N Engl J Med. 2016 Nov 3;375(18):1717-1725. doi: 10.1056/NEJMoa1604221.
2
[Not Available].
Presse Med. 2016 Sep;45(9):719-22. doi: 10.1016/j.lpm.2016.08.003.
3
Implications of the BIA-102474-101 study for review of first-into-human clinical trials.
Br J Clin Pharmacol. 2016 Apr;81(4):582-6. doi: 10.1111/bcp.12920.
4
Why is it hard to terminate failing projects in pharmaceutical R&D?
Nat Rev Drug Discov. 2015 Oct;14(10):663-4. doi: 10.1038/nrd4725. Epub 2015 Aug 21.
5
Factors influencing non-approval of new drugs in Europe.
Nat Rev Drug Discov. 2012 Dec;11(12):903-4. doi: 10.1038/nrd3894.
6
New drug approval success rate in Europe in 2009.
Nat Rev Drug Discov. 2010 May;9(5):355-6. doi: 10.1038/nrd3169.
Zotero 插件